COLL · Collegium Pharmaceutical, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $193.52M | - | $209.36M | $188.00M | $177.76M | - | $159.30M | $145.28M | $144.92M | - |
| Cost of Revenue | $76.27M | - | $80.19M | $79.62M | $80.43M | - | $62.51M | $54.47M | $53.47M | - |
| Gross Profit | $117.25M | - | $129.17M | $108.38M | $97.32M | - | $96.79M | $90.81M | $91.46M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $86.35M | - | $67.10M | $73.64M | $76.42M | - | $61.95M | $43.34M | $41.98M | - |
| Total Operating Expenses | $86.35M | - | $67.08M | $73.28M | $75.64M | - | $61.95M | $43.34M | $41.98M | - |
| D&A | $463.0K | - | $1.03M | $952.0K | $1.09M | - | - | - | $917.0K | - |
| Operating Income | $30.90M | - | $62.09M | $35.10M | $21.69M | - | $34.84M | $47.47M | $49.47M | - |
| Interest Expense | $15.86M | - | $21.77M | $20.46M | $20.79M | - | $18.39M | $15.59M | $17.34M | - |
| Income Tax | $4.24M | - | $11.93M | $5.04M | $705.0K | - | $6.25M | $9.49M | $8.91M | - |
| Net Income | $14.50M | - | $31.51M | $11.98M | $2.42M | - | $9.34M | $19.61M | $27.71M | - |
| EPS - Basic | $0.45 | - | $1.00 | $0.38 | $0.08 | - | $0.29 | $0.60 | $0.86 | - |
| EPS - Diluted | $0.40 | - | $0.84 | $0.34 | $0.07 | - | $0.27 | $0.52 | $0.71 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $268.65M | $231.25M | $150.10M | $117.35M | $96.19M | $70.56M | $38.96M | $172.89M | $228.61M | $238.95M |
| Accounts Receivable | $228.76M | $211.33M | $233.95M | $213.02M | $228.71M | $228.54M | $228.46M | $183.85M | $174.69M | $179.53M |
| Inventory | $42.74M | $40.91M | $38.05M | $38.15M | $37.22M | $35.56M | $38.03M | $27.86M | $31.28M | $32.33M |
| Accounts Payable | $6.83M | $10.66M | $7.65M | $10.89M | $17.85M | $3.93M | $3.14M | $2.41M | $6.02M | $8.69M |
| Current Assets | $745.67M | $691.41M | $613.87M | $549.21M | $527.55M | $482.26M | $443.81M | $510.20M | $539.26M | $537.60M |
| Total Assets | $1.65B | $1.66B | $1.61B | $1.59B | $1.63B | $1.66B | $1.64B | $1.05B | $1.11B | $1.14B |
| Current Liabilities | $434.97M | $440.03M | $452.93M | $464.61M | $486.71M | $509.51M | $459.43M | $461.72M | $446.44M | $457.92M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.34B | $1.36B | $1.33B | $1.36B | $1.40B | $1.43B | $1.40B | $836.80M | $892.08M | $947.88M |
| Stockholders' Equity | $312.42M | $301.68M | $274.81M | $232.21M | $234.43M | $228.84M | $234.28M | $216.58M | $222.17M | $195.43M |
| Retained Earnings | ($86.63M) | ($101.13M) | ($118.09M) | ($149.60M) | ($161.58M) | ($164.00M) | ($176.53M) | ($185.87M) | ($205.48M) | ($233.19M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $57.11M | - | - | - | $55.40M | - | - | - | $61.94M | - |
| Investing Cash Flow | $1.63M | - | - | - | ($9.68M) | - | - | - | ($18.13M) | - |
| Financing Cash Flow | ($21.34M) | - | - | - | ($25.24M) | - | - | - | ($54.15M) | - |
| CapEx | $270.0K | - | - | - | $798.0K | - | - | - | $568.0K | - |
| Free Cash Flow | $56.84M | - | - | - | $54.60M | - | - | - | $61.37M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 60.6% | - | 61.7% | 57.7% | 54.8% | - | 60.8% | 62.5% | 63.1% | - |
| Operating margin | 16.0% | - | 29.7% | 18.7% | 12.2% | - | 21.9% | 32.7% | 34.1% | - |
| EBITDA margin | 16.2% | - | 30.1% | 19.2% | 12.8% | - | - | - | 34.8% | - |
| Net margin | 7.5% | - | 15.0% | 6.4% | 1.4% | - | 5.9% | 13.5% | 19.1% | - |
| Free cash flow margin | 29.4% | - | - | - | 30.7% | - | - | - | 42.3% | - |
| FCF / Net income | 3.92 | - | - | - | 22.59 | - | - | - | 2.21 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 44.6% | - | 32.1% | 39.2% | 43.0% | - | 38.9% | 29.8% | 29.0% | - |
| Effective tax rate | 22.6% | - | 27.5% | 29.6% | 22.6% | - | 40.1% | 32.6% | 24.3% | - |
| Return on assets | 0.9% | - | 2.0% | 0.8% | 0.1% | - | 0.6% | 1.9% | 2.5% | - |
| Return on equity | 4.6% | - | 11.5% | 5.2% | 1.0% | - | 4.0% | 9.1% | 12.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.71 | 1.57 | 1.36 | 1.18 | 1.08 | 0.95 | 0.97 | 1.11 | 1.21 | 1.17 |
| Quick ratio | 1.62 | 1.48 | 1.27 | 1.10 | 1.01 | 0.88 | 0.88 | 1.04 | 1.14 | 1.10 |
| Cash ratio | 0.62 | 0.53 | 0.33 | 0.25 | 0.20 | 0.14 | 0.08 | 0.37 | 0.51 | 0.52 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 1.9x | - | 2.9x | 1.7x | 1.0x | - | 1.9x | 3.0x | 2.9x | - |
| Equity multiplier | 5.29 | 5.49 | 5.85 | 6.86 | 6.96 | 7.27 | 6.98 | 4.86 | 5.02 | 5.85 |
| Liabilities / Assets | 0.81 | 0.82 | 0.83 | 0.85 | 0.86 | 0.86 | 0.86 | 0.79 | 0.80 | 0.83 |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | - | 0.13 | 0.12 | 0.11 | - | 0.10 | 0.14 | 0.13 | - |
| Inventory turnover | 1.78 | - | 2.11 | 2.09 | 2.16 | - | 1.64 | 1.95 | 1.71 | - |
| Days sales outstanding | 431d | - | 408d | 414d | 470d | - | 523d | 462d | 440d | - |
| Days inventory outstanding | 205d | - | 173d | 175d | 169d | - | 222d | 187d | 214d | - |
| Days payable outstanding | 33d | - | 35d | 50d | 81d | - | 18d | 16d | 41d | - |
| Cash conversion cycle | 603d | - | 546d | 539d | 558d | - | 727d | 632d | 612d | - |
| Valuation | ||||||||||
| P / E | 82.7x | - | 41.7x | 87.0x | 426.4x | - | 143.1x | 61.9x | 54.7x | - |
| P / B | 4.2x | - | 5.0x | 5.0x | 4.2x | - | 6.6x | 6.0x | 7.2x | - |
| P / S | 6.8x | - | 6.6x | 6.1x | 5.5x | - | 9.7x | 9.0x | 11.1x | - |
| EV / EBITDA | 33.7x | - | 19.5x | 28.8x | 38.8x | - | - | - | 27.4x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 8.9% | - | 31.4% | 29.4% | 22.7% | - | 16.5% | 7.2% | 0.1% | - |
| Revenue CAGR (3y) | 10.2% | - | 18.1% | 15.0% | 28.5% | - | 26.4% | 20.5% | 18.2% | - |
| Revenue CAGR (5y) | 17.1% | - | 21.5% | 19.2% | 18.4% | - | 16.9% | 14.1% | 14.2% | - |
| Gross profit growth (YoY) | 20.5% | - | 33.4% | 19.4% | 6.4% | - | 20.5% | 23.0% | 18.2% | - |
| Operating income growth (YoY) | 42.5% | - | 78.2% | -26.0% | -56.2% | - | -22.6% | 33.2% | 100.9% | - |
| Net income growth (YoY) | 499.8% | - | 237.5% | -38.9% | -91.3% | - | -54.8% | 50.7% | - | - |
| EPS growth (YoY) | 471.4% | - | 211.1% | -34.6% | -90.1% | - | -49.1% | 52.9% | - | - |
| EPS CAGR (3y) | - | - | 338.0% | - | - | - | 7.1% | -33.8% | 20.1% | - |
| EPS CAGR (5y) | -0.5% | - | 21.3% | 8.1% | 47.6% | - | - | - | - | - |
| FCF growth (YoY) | 4.1% | - | - | - | -11.0% | - | - | - | 123.2% | - |
| FCF CAGR (5y) | 23.1% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 33.3% | 31.8% | 17.3% | 7.2% | 5.5% | 17.1% | 31.0% | 7.9% | 23.6% | 0.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$780.57M totalSingle Reportable Segment$780.57M · 100.0%
Product / service
$780.57M totalBelbuca$221.65M · 28.4%
Xtampza ER$199.31M · 25.5%
Jornay Pm$148.86M · 19.1%
Nucynta IR$115.31M · 14.8%
Nucynta ER$80.98M · 10.4%
Symproic And Other$14.45M · 1.9%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing COLLEGIUM PHARMACEUTICAL against the 5 most active filers in the same SIC group.